论文部分内容阅读
为改善布地奈德的溶解度和吸收,制备并评价了布地奈德固体脂质纳米粒(BUD-SLNs)。通过计算部分溶解度参数选择了单硬脂酸甘油酯作为脂材。经处方优化采用乳化-超声分散的方法制备的BUD-SLNs,包封率为(97.77±2.60)%;平均粒径是147.3nm,粒径分布均匀(PDI=0.228)。透射电镜下可见圆整颗粒。差热分析和X射线衍射实验的结果表明BUD以分子形式分散在SLNs中,体外释放结果表明BUD-SLNs符合双相动力学方程,属于均相骨架结构。研究结果为BUD-SLNs在肺部给药奠定了基础。
To improve the solubility and absorption of budesonide, budesonide solid lipid nanoparticles (BUD-SLNs) were prepared and evaluated. Glycerol monostearate was chosen as the lipid material by calculating partial solubility parameters. The encapsulation efficiency of BUD-SLNs prepared by the emulsification-ultrasonic dispersion method was (97.77 ± 2.60)%. The average particle size was 147.3nm and the particle size distribution was uniform (PDI = 0.228). Transmission electron microscopy can see rounded particles. Differential thermal analysis and X-ray diffraction results show that BUD molecules are dispersed in SLNs. The in vitro release results show that BUD-SLNs are in accordance with the biphasic kinetic equation and belong to the homogeneous framework. The results laid the foundation for the administration of BUD-SLNs in the lungs.